Clinical Trials Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Reports from Memorial Sloan Kettering Cancer Center, Department of Medicine advance knowledge in cancer vaccines
August 27th, 2007
Research findings, "A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma," are discussed in a new report. "We performed a phase I pilot study to determine if autologous vaccine HSPPC-96 (gp96, Oncophage) could be purified from completely resected pancreas adenocarcinomas, to determine patient tolerance of vaccine and to explore immune responses and clinical outcomes of these patients. Subjects were vaccinated with 5 microg of autologous HSPPC-96 weekly for 4 doses," scientists in the United States report. "Serial ELISPOT assays of T cells for antitumor reactivity were performed. Subjects received...
Source: Clinical Trials Week (2007-08-27)
|
